TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase III Multi-national, Multi-centre, Double-blind Placebo-controlled Parallel Group, 26 Week Study to Assess the Maintenance of Clinical Response to Humanised Anti-TNF PEG Conjugate, CDP870 400 mg sc, (Dosed 4-weekly From Weeks 8 to 24), in the Treatment of Patients With Active Crohn's Disease Who Have Responded to Open Induction Therapy (Dosed at Weeks 0, 2 and 4) With CDP870
Brief Summary: A 26 week maintenance study of CDP870 in Crohn's disease


Options:
A: Arm Label: Population 1: Placebo SC followed by ustekinumab SC; Type: EXPERIMENTAL; Interventions: Drug: Ustekinumab 90 mg, Drug: Placebo SC | Arm Label: Population 1: Ustekinumab SC followed by Placebo SC:; Type: EXPERIMENTAL; Interventions: Drug: Ustekinumab 90 mg, Drug: Placebo SC | Arm Label: Population 1: Placebo IV followed by ustekinumab IV; Type: EXPERIMENTAL; Interventions: Drug: Ustekinumab 4.5 mg/kg, Drug: Placebo IV | Arm Label: Population 1: Ustekinumab IV followed by Placebo IV:; Type: EXPERIMENTAL; Interventions: Drug: Ustekinumab 4.5 mg/kg, Drug: Placebo IV | Arm Label: Population 2: Ustekinumab SC; Type: EXPERIMENTAL; Interventions: Drug: Ustekinumab 90 mg | Arm Label: Population 2: Ustekinumab IV; Type: EXPERIMENTAL; Interventions: Drug: Ustekinumab 4.5 mg/kg | Intervention Type: DRUG; Name: Ustekinumab 90 mg; Assigned to Arm(s): Population 1: Placebo SC followed by ustekinumab SC, Population 1: Ustekinumab SC followed by Placebo SC:, Population 2: Ustekinumab SC | Intervention Type: DRUG; Name: Ustekinumab 4.5 mg/kg; Assigned to Arm(s): Population 1: Placebo IV followed by ustekinumab IV, Population 1: Ustekinumab IV followed by Placebo IV:, Population 2: Ustekinumab IV | Intervention Type: DRUG; Name: Placebo SC; Assigned to Arm(s): Population 1: Placebo SC followed by ustekinumab SC, Population 1: Ustekinumab SC followed by Placebo SC: | Intervention Type: DRUG; Name: Placebo IV; Assigned to Arm(s): Population 1: Placebo IV followed by ustekinumab IV, Population 1: Ustekinumab IV followed by Placebo IV:
B: Intervention Type: DRUG; Name: Certolizumab Pegol (CDP870); Assigned to Arm(s): N/A
C: Arm Label: A; Type: EXPERIMENTAL; Interventions: Drug: ABT-874 | Arm Label: B; Type: ACTIVE_COMPARATOR; Interventions: Drug: Methotrexate | Intervention Type: DRUG; Name: ABT-874; Assigned to Arm(s): A | Intervention Type: DRUG; Name: Methotrexate; Assigned to Arm(s): B
D: Arm Label: 003; Type: EXPERIMENTAL; Interventions: Other: infliximab (IFX) infusion; azathioprine (AZA) caps | Arm Label: 001; Type: EXPERIMENTAL; Interventions: Drug: infliximab (IFX) placebo infusion; azathioprine (AZA) caps | Arm Label: 002; Type: EXPERIMENTAL; Interventions: Biological: infliximab infusion; AZA placebo caps | Intervention Type: BIOLOGICAL; Name: infliximab infusion; AZA placebo caps; Assigned to Arm(s): 002 | Intervention Type: OTHER; Name: infliximab (IFX) infusion; azathioprine (AZA) caps; Assigned to Arm(s): 003 | Intervention Type: DRUG; Name: infliximab (IFX) placebo infusion; azathioprine (AZA) caps; Assigned to Arm(s): 001

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase III Multi-national, Multi-centre, Double-blind Placebo-controlled Parallel Group, 26 Week Study to Assess the Maintenance of Clinical Response to Humanised Anti-TNF PEG Conjugate, CDP870 400 mg sc, (Dosed 4-weekly From Weeks 8 to 24), in the Treatment of Patients With Active Crohn's Disease Who Have Responded to Open Induction Therapy (Dosed at Weeks 0, 2 and 4) With CDP870
Brief Summary: A 26 week maintenance study of CDP870 in Crohn's disease


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Methotrexate, Drug: tocilizumab [RoActemra/Actemra] | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: Methotrexate, Drug: tocilizumab [RoActemra/Actemra] | Arm Label: 3; Type: PLACEBO_COMPARATOR; Interventions: Drug: Methotrexate, Drug: Placebo | Intervention Type: DRUG; Name: Methotrexate; Assigned to Arm(s): 1, 2, 3 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 3 | Intervention Type: DRUG; Name: tocilizumab [RoActemra/Actemra]; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: tocilizumab [RoActemra/Actemra]; Assigned to Arm(s): 1
B: Intervention Type: DRUG; Name: Infliximab; Assigned to Arm(s): N/A
C: Intervention Type: DRUG; Name: Certolizumab Pegol (CDP870); Assigned to Arm(s): N/A
D: Intervention Type: DRUG; Name: Etanercept; Assigned to Arm(s): N/A

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase III Multi-national, Multi-centre, Double-blind Placebo-controlled Parallel Group, 26 Week Study to Assess the Safety and Efficacy of the Humanised Anti-TNF PEG Conjugate, CDP870 400 mg sc, (Dosed at Weeks 0, 2, 4 Then 4-weekly to Week 24), in the Treatment of Patients With Active Crohn's Disease
Brief Summary: A 26 week study to examine the efficacy, safety and pharmacokinetics of CDP870 in Crohn's disease


Options:
A: Intervention Type: DRUG; Name: Certolizumab Pegol (CDP870); Assigned to Arm(s): N/A
B: Intervention Type: DRUG; Name: Certolizumab Pegol (CDP870); Assigned to Arm(s): N/A
C: Arm Label: Certolizumab Pegol; Type: EXPERIMENTAL; Interventions: Biological: Certolizumab Pegol (CDP870) | Intervention Type: BIOLOGICAL; Name: Certolizumab Pegol (CDP870); Assigned to Arm(s): Certolizumab Pegol
D: Arm Label: Pharmacokinetic samples; Type: EXPERIMENTAL; Interventions: Procedure: Blood sampling from mother, Procedure: Blood sampling from infant, Procedure: Blood sampling from umbilical cord, Biological: Certolizumab Pegol | Intervention Type: PROCEDURE; Name: Blood sampling from mother; Assigned to Arm(s): Pharmacokinetic samples | Intervention Type: PROCEDURE; Name: Blood sampling from infant; Assigned to Arm(s): Pharmacokinetic samples | Intervention Type: PROCEDURE; Name: Blood sampling from umbilical cord; Assigned to Arm(s): Pharmacokinetic samples | Intervention Type: BIOLOGICAL; Name: Certolizumab Pegol; Assigned to Arm(s): Pharmacokinetic samples

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase III Multi-national, Multi-centre, Double-blind Placebo-controlled Parallel Group, 26 Week Study to Assess the Safety and Efficacy of the Humanised Anti-TNF PEG Conjugate, CDP870 400 mg sc, (Dosed at Weeks 0, 2, 4 Then 4-weekly to Week 24), in the Treatment of Patients With Active Crohn's Disease
Brief Summary: A 26 week study to examine the efficacy, safety and pharmacokinetics of CDP870 in Crohn's disease


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: tocilizumab [RoActemra/Actemra], Drug: Methotrexate | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: tocilizumab [RoActemra/Actemra], Drug: Methotrexate | Arm Label: 3; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Drug: Methotrexate | Intervention Type: DRUG; Name: tocilizumab [RoActemra/Actemra]; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: tocilizumab [RoActemra/Actemra]; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 3 | Intervention Type: DRUG; Name: Methotrexate; Assigned to Arm(s): 1, 2, 3
B: Intervention Type: DRUG; Name: adalimumab; Assigned to Arm(s): N/A
C: Arm Label: Group 1: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Biological: Golimumab 50 mg | Arm Label: Group 2: Golimumab 50 mg; Type: EXPERIMENTAL; Interventions: Biological: Golimumab 50 mg | Arm Label: Group 3: Golimumab 100 mg; Type: EXPERIMENTAL; Interventions: Biological: Golimumab 100 mg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Group 1: Placebo | Intervention Type: BIOLOGICAL; Name: Golimumab 50 mg; Assigned to Arm(s): Group 1: Placebo, Group 2: Golimumab 50 mg | Intervention Type: BIOLOGICAL; Name: Golimumab 100 mg; Assigned to Arm(s): Group 3: Golimumab 100 mg
D: Intervention Type: DRUG; Name: Certolizumab Pegol (CDP870); Assigned to Arm(s): N/A

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase III Multi-national, Multi-centre, Double-blind Placebo-controlled Parallel Group, 26 Week Study to Assess the Safety and Efficacy of the Humanised Anti-TNF PEG Conjugate, CDP870 400 mg sc, (Dosed at Weeks 0, 2, 4 Then 4-weekly to Week 24), in the Treatment of Patients With Active Crohn's Disease
Brief Summary: A 26 week study to examine the efficacy, safety and pharmacokinetics of CDP870 in Crohn's disease


Options:
A: Arm Label: A; Type: EXPERIMENTAL; Interventions: Drug: budesonide | Arm Label: B; Type: ACTIVE_COMPARATOR; Interventions: Drug: budesonide | Intervention Type: DRUG; Name: budesonide; Assigned to Arm(s): A | Intervention Type: DRUG; Name: budesonide; Assigned to Arm(s): B
B: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: D9421-C, 9mg | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: D9421-C, 15mg | Arm Label: 3; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: D9421-C, 9mg; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: D9421-C, 15mg; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 3
C: Intervention Type: DRUG; Name: Certolizumab Pegol (CDP870); Assigned to Arm(s): N/A
D: Arm Label: Vedolizumab; Type: EXPERIMENTAL; Interventions: Drug: vedolizumab | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Intervention Type: DRUG; Name: vedolizumab; Assigned to Arm(s): Vedolizumab | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: "C.A.T.C.H.-I.T." Competent Adulthood Transition With Cognitive, Humanistic and Interpersonal Teaching
Brief Summary: The purpose of this study is to adapt depression prevention interventions of proven benefit to the primary care setting in a manner that would be acceptable and potentially available to young adults in the community.


Options:
A: Arm Label: Intrinsic Motivation; Type: EXPERIMENTAL; Interventions: Behavioral: MI + CATCH-IT Internet Site | Arm Label: Extrinsic Motivation; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: BA (brief advice) + CATCH-IT Internet site | Intervention Type: BEHAVIORAL; Name: MI + CATCH-IT Internet Site; Assigned to Arm(s): Intrinsic Motivation | Intervention Type: BEHAVIORAL; Name: BA (brief advice) + CATCH-IT Internet site; Assigned to Arm(s): Extrinsic Motivation
B: Intervention Type: BEHAVIORAL; Name: Screening (Behavior); Assigned to Arm(s): N/A
C: Arm Label: Clinic-based Educational Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Clinic-based Educational Intervention | Arm Label: Usual Care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Clinic-based Educational Intervention; Assigned to Arm(s): Clinic-based Educational Intervention
D: Arm Label: SMS and Internet; Type: EXPERIMENTAL; Interventions: Behavioral: MD2ME | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: MD2ME; Assigned to Arm(s): SMS and Internet

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: "C.A.T.C.H.-I.T." Competent Adulthood Transition With Cognitive, Humanistic and Interpersonal Teaching
Brief Summary: The purpose of this study is to adapt depression prevention interventions of proven benefit to the primary care setting in a manner that would be acceptable and potentially available to young adults in the community.


Options:
A: Intervention Type: BEHAVIORAL; Name: Screening (Behavior); Assigned to Arm(s): N/A
B: Arm Label: Mood monitoring; Type: EXPERIMENTAL; Interventions: Device: Mobile Tracking Young People's Experiences (mobiletype) | Arm Label: Comparison monitoring program; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DEVICE; Name: Mobile Tracking Young People's Experiences (mobiletype); Assigned to Arm(s): Mood monitoring
C: Arm Label: CATCH-IT; Type: EXPERIMENTAL; Interventions: Behavioral: CATCH-IT | Arm Label: Health Education; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: CATCH-IT; Assigned to Arm(s): CATCH-IT
D: Arm Label: Intrinsic Motivation; Type: EXPERIMENTAL; Interventions: Behavioral: MI + CATCH-IT Internet Site | Arm Label: Extrinsic Motivation; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: BA (brief advice) + CATCH-IT Internet site | Intervention Type: BEHAVIORAL; Name: MI + CATCH-IT Internet Site; Assigned to Arm(s): Intrinsic Motivation | Intervention Type: BEHAVIORAL; Name: BA (brief advice) + CATCH-IT Internet site; Assigned to Arm(s): Extrinsic Motivation

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Psychological Support for Patients With an Implantable Cardioverter Defibrillator
Brief Summary: About 30% of patients survive a cardiac arrest, and the majority of these receive an implantable cardioverter defibrillator (ICD) for prevention of sudden cardiac death (SCD). While ICD therapy offers survival benefit over drug therapy, there remain significant quality of life (QL) issues. About 50% of patients experience chronic anxiety about receiving an ICD shock. Anxiety and depression in turn appear to predispose to more arrhythmias necessitating ICD therapy. The aims of the current study are:

1. to evaluate a 8-session psychosocial intervention to help patients cope effectively with receiving an ICD for secondary prevention of SCD,
2. to determine if baseline measures of depression and anxiety predict ICD therapies (i.e., anti-tachycardia pace terminations and shocks); and
3. to explore if the psychosocial intervention results in less need for appropriate ICD therapies.


Options:
A: Arm Label: Cognitive Behavior Therapy - males; Type: EXPERIMENTAL; Interventions: Behavioral: Cognitive Behaviour Therapy (CBT) | Arm Label: Cognitive Behavior Therapy - females; Type: EXPERIMENTAL; Interventions: Behavioral: Cognitive Behaviour Therapy (CBT) | Arm Label: Usual Cardiac Care - Males; Type: ACTIVE_COMPARATOR; Interventions: Other: Usual Cardiac Care (UCC) | Arm Label: Usual Cardiac Care - females; Type: ACTIVE_COMPARATOR; Interventions: Other: Usual Cardiac Care (UCC) | Intervention Type: BEHAVIORAL; Name: Cognitive Behaviour Therapy (CBT); Assigned to Arm(s): Cognitive Behavior Therapy - females, Cognitive Behavior Therapy - males | Intervention Type: OTHER; Name: Usual Cardiac Care (UCC); Assigned to Arm(s): Usual Cardiac Care - Males, Usual Cardiac Care - females
B: Arm Label: Aerobic Exercise Program; Type: EXPERIMENTAL; Interventions: Behavioral: Aerobic Exercise Program | Arm Label: Usual Care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Aerobic Exercise Program; Assigned to Arm(s): Aerobic Exercise Program
C: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Other: rehabilitation | Arm Label: 2; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: rehabilitation; Assigned to Arm(s): 1
D: Arm Label: Cognitive Behavioral Stress Management; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Cognitive Behavioral Stress Management (CBSM) | Arm Label: Patient Education; Type: ACTIVE_COMPARATOR; Interventions: Other: Patient Education | Intervention Type: BEHAVIORAL; Name: Cognitive Behavioral Stress Management (CBSM); Assigned to Arm(s): Cognitive Behavioral Stress Management | Intervention Type: OTHER; Name: Patient Education; Assigned to Arm(s): Patient Education

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A 12-week Randomised, Double Blind, Placebo Controlled, Parallel Group Trial Evaluating the Efficacy and Safety of Inhaled Tiotropium 18μg q.d. in Patients With COPD and a Concomitant Diagnosis of Asthma
Brief Summary: The primary objective of this study is to demonstrate the superiority of tiotropium compared to placebo in the treatment of patients with COPD and a concomitant diagnosis of asthma


Options:
A: Arm Label: Indacaterol 300 μg plus placebo to formoterol; Type: EXPERIMENTAL; Interventions: Drug: Indacaterol, Drug: Placebo to formoterol | Arm Label: Indacaterol 600 μg plus placebo to formoterol; Type: EXPERIMENTAL; Interventions: Drug: Indacaterol, Drug: Placebo to formoterol | Arm Label: Formoterol 12 μg plus placebo to indacaterol; Type: ACTIVE_COMPARATOR; Interventions: Drug: Formoterol, Drug: Placebo to indacaterol | Arm Label: Placebo to indacaterol plus placebo to formoterol; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo to indacaterol, Drug: Placebo to formoterol | Intervention Type: DRUG; Name: Indacaterol; Assigned to Arm(s): Indacaterol 300 μg plus placebo to formoterol, Indacaterol 600 μg plus placebo to formoterol | Intervention Type: DRUG; Name: Formoterol; Assigned to Arm(s): Formoterol 12 μg plus placebo to indacaterol | Intervention Type: DRUG; Name: Placebo to indacaterol; Assigned to Arm(s): Formoterol 12 μg plus placebo to indacaterol, Placebo to indacaterol plus placebo to formoterol | Intervention Type: DRUG; Name: Placebo to formoterol; Assigned to Arm(s): Indacaterol 300 μg plus placebo to formoterol, Indacaterol 600 μg plus placebo to formoterol, Placebo to indacaterol plus placebo to formoterol
B: Intervention Type: DRUG; Name: Tiotropium inhalation capsules; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Placebo inhalation capsules; Assigned to Arm(s): N/A
C: Intervention Type: DRUG; Name: Fluticasone Propionate/Salmeterol Combination Product; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Salmeterol; Assigned to Arm(s): N/A
D: Intervention Type: DEVICE; Name: 5 mcg once daily tiotropium inhalation solution delivered by the Respimat inhaler; Assigned to Arm(s): N/A | Intervention Type: DEVICE; Name: 10 mcg once daily tiotropium inhalation solution delivered by the Respimat inhaler; Assigned to Arm(s): N/A

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A 12-week Randomised, Double Blind, Placebo Controlled, Parallel Group Trial Evaluating the Efficacy and Safety of Inhaled Tiotropium 18μg q.d. in Patients With COPD and a Concomitant Diagnosis of Asthma
Brief Summary: The primary objective of this study is to demonstrate the superiority of tiotropium compared to placebo in the treatment of patients with COPD and a concomitant diagnosis of asthma


Options:
A: Intervention Type: DRUG; Name: Tiotropium bromide; Assigned to Arm(s): N/A
B: Intervention Type: DRUG; Name: tiotropium; Assigned to Arm(s): N/A
C: Intervention Type: DRUG; Name: Tiotropium inhalation capsules; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Placebo inhalation capsules; Assigned to Arm(s): N/A
D: Intervention Type: DEVICE; Name: 5 mcg once daily tiotropium inhalation solution delivered by the Respimat inhaler; Assigned to Arm(s): N/A | Intervention Type: DEVICE; Name: 10 mcg once daily tiotropium inhalation solution delivered by the Respimat inhaler; Assigned to Arm(s): N/A

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: ECASS III - European Cooperative Acute Stroke Study III: A Placebo Controlled Trial of Alteplase (Rt-PA) in Acute Ischemic Hemispheric Stroke Where Thrombolysis is Initiated Between 3 and 4 Hours 30 Minutes After Stroke Onset
Brief Summary: To collect additional confirmatory data on alteplase(rt-PA) in the European setting and to demonstrate that the treatment of patients between 3 and 4.30 hours of onset of symptoms of acute ischemic stroke with rt-PA compared to placebo-treated patients will result in an improved clinical outcome without increase of fatality rate.


Options:
A: Intervention Type: DRUG; Name: Eicosapentaenoic acid ethyl ester(EPADEL Capsule 300 TM); Assigned to Arm(s): N/A
B: Arm Label: Pikasol; Type: ACTIVE_COMPARATOR; Interventions: Drug: Pikasol | Arm Label: Corn oil; Type: PLACEBO_COMPARATOR; Interventions: Other: Corn oil | Intervention Type: DRUG; Name: Pikasol; Assigned to Arm(s): Pikasol | Intervention Type: OTHER; Name: Corn oil; Assigned to Arm(s): Corn oil
C: Intervention Type: DRUG; Name: rt-PA 0.9 mg/kg verum or placebo Intravenous; Assigned to Arm(s): N/A
D: Arm Label: A; Type: EXPERIMENTAL; Interventions: Drug: Eicosapentaenoic acid ethyl ester | Arm Label: B; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: Eicosapentaenoic acid ethyl ester; Assigned to Arm(s): A

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: ECASS III - European Cooperative Acute Stroke Study III: A Placebo Controlled Trial of Alteplase (Rt-PA) in Acute Ischemic Hemispheric Stroke Where Thrombolysis is Initiated Between 3 and 4 Hours 30 Minutes After Stroke Onset
Brief Summary: To collect additional confirmatory data on alteplase(rt-PA) in the European setting and to demonstrate that the treatment of patients between 3 and 4.30 hours of onset of symptoms of acute ischemic stroke with rt-PA compared to placebo-treated patients will result in an improved clinical outcome without increase of fatality rate.


Options:
A: Intervention Type: DRUG; Name: rt-PA 0.9 mg/kg verum or placebo Intravenous; Assigned to Arm(s): N/A
B: Arm Label: Thrombectomy; Type: ACTIVE_COMPARATOR; Interventions: Device: Thrombectomy | Arm Label: Best medical care; Type: OTHER; Interventions: Other: Best medical care | Intervention Type: DEVICE; Name: Thrombectomy; Assigned to Arm(s): Thrombectomy | Intervention Type: OTHER; Name: Best medical care; Assigned to Arm(s): Best medical care
C: Arm Label: Medical Management; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Intra-arterial Therapy; Type: EXPERIMENTAL; Interventions: Procedure: Intra-arterial Therapy | Intervention Type: PROCEDURE; Name: Intra-arterial Therapy; Assigned to Arm(s): Intra-arterial Therapy
D: Arm Label: Higher Systolic Blood Pressure (SBP) Target; Type: EXPERIMENTAL; Interventions: Drug: Nicardipine, Drug: Labetalol, Drug: Hydralazine | Arm Label: Lower SBP (<160 mmHg) Target; Type: EXPERIMENTAL; Interventions: Drug: Nicardipine, Drug: Labetalol, Drug: Hydralazine | Arm Label: Lower SBP (<140mmHg) Target; Type: EXPERIMENTAL; Interventions: Drug: Nicardipine, Drug: Labetalol, Drug: Hydralazine | Intervention Type: DRUG; Name: Nicardipine; Assigned to Arm(s): Higher Systolic Blood Pressure (SBP) Target, Lower SBP (<140mmHg) Target, Lower SBP (<160 mmHg) Target | Intervention Type: DRUG; Name: Labetalol; Assigned to Arm(s): Higher Systolic Blood Pressure (SBP) Target, Lower SBP (<140mmHg) Target, Lower SBP (<160 mmHg) Target | Intervention Type: DRUG; Name: Hydralazine; Assigned to Arm(s): Higher Systolic Blood Pressure (SBP) Target, Lower SBP (<140mmHg) Target, Lower SBP (<160 mmHg) Target

Answer: A